doi: 10.5489/cuaj.2874.
Follicle-stimulating hormone: A potential surrogate marker for androgen deprivation therapy oncological and systemic effects
Affiliations
- PMID: 26085887
- PMCID: PMC4455647
- DOI: 10.5489/cuaj.2874
Item in Clipboard
Follicle-stimulating hormone: A potential surrogate marker for androgen deprivation therapy oncological and systemic effects
Can Urol Assoc J.
2015 Mar-Apr.
No abstract available
Comment on
-
Serum follicle-stimulating hormone levels predict time to development of castration-resistant prostate cancer.Can Urol Assoc J. 2015 Mar-Apr;9(3-4):122-7. doi: 10.5489/cuaj.2545. Can Urol Assoc J. 2015. PMID: 26085869 Free PMC article.
Similar articles
-
Adrenocorticotropic hormone is involved in regulation of androgen synthesis in men receiving androgen deprivation therapy for localized prostate cancer.J Urol. 2010 Nov;184(5):1971-6. doi: 10.1016/j.juro.2010.06.115. J Urol. 2010. PMID: 20884032
-
Are GnRH and FSH potentially damaging factors in the cardiovascular system?Pharmazie. 2018 Apr 2;73(4):187-190. doi: 10.1691/ph.2018.7992. Pharmazie. 2018. PMID: 29609683 Review.
-
Dose-escalated abarelix in androgen-independent prostate cancer: a phase I study.Anticancer Drugs. 2006 Oct;17(9):1075-9. doi: 10.1097/01.cad.0000231476.84782.55. Anticancer Drugs. 2006. PMID: 17001181 Clinical Trial.
-
The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy.Urol Oncol. 2017 May;35(5):183-191. doi: 10.1016/j.urolonc.2017.01.025. Epub 2017 Mar 18. Urol Oncol. 2017. PMID: 28325650 Review.
-
Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study.J Urol. 2008 May;179(5):1830-7; discussion 1837. doi: 10.1016/j.juro.2008.01.022. Epub 2008 Mar 18. J Urol. 2008. PMID: 18353378
Cited by
-
A comprehensive review on the effects of sex hormones on chemotherapy-induced cardiotoxicity: are they lucrative or unprofitable?Cardiooncology. 2024 Dec 3;10(1):86. doi: 10.1186/s40959-024-00293-3. Cardiooncology. 2024. PMID: 39627907 Free PMC article. Review.
-
Are higher follicle-stimulating hormone levels before androgen deprivation therapy for prostate cancer associated with oncological and cardiac outcomes and overall survival?-a population-level analysis.Transl Androl Urol. 2023 Oct 31;12(10):1540-1549. doi: 10.21037/tau-23-114. Epub 2023 Oct 16. Transl Androl Urol. 2023. PMID: 37969776 Free PMC article.
-
Systems Oncology: Bridging Pancreatic and Castrate Resistant Prostate Cancer.Pathol Oncol Res. 2019 Oct;25(4):1269-1277. doi: 10.1007/s12253-018-0467-8. Epub 2018 Sep 16. Pathol Oncol Res. 2019. PMID: 30220022 Review.
-
Estetrol Inhibits the Prostate Cancer Tumor Stimulators FSH and IGF-1.J Clin Med. 2024 Oct 8;13(19):5996. doi: 10.3390/jcm13195996. J Clin Med. 2024. PMID: 39408055 Free PMC article.
-
Effect of ovariohysterectomy on queen myocardial function: echocardiographic evidence.Vet Res Forum. 2023;14(9):495-499. doi: 10.30466/vrf.2022.552942.3456. Epub 2023 Sep 15. Vet Res Forum. 2023. PMID: 37814657 Free PMC article.
References
-
- Klotz L, O’Callaghan C, Ding K, et al. Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: A secondary analysis of the PR-7 trial of intermittent versus continuous ADT. J Clin Oncol. 2015;33:1151–6. doi: 10.1200/JCO.2014.58.2973. . Epub 2015 Mar 2. - DOI - PMC - PubMed
-
- Crawford ED, Rove KO, Schally AV, et al. The role of the FSH system in the development and progression of prostate cancer. Am J Hematol Oncol. 2015;10:5–13.
-
- Heracek J, Urban M, Sachova J, et al. The endocrine profiles in men with localized and locally advanced prostate cancer treated with radical prostatectomy. Neuro Endocrinol Lett. 2007;28:45–51. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources